近日，天士力自主研发的同种异体脂肪间充质基质细胞注射液（NR-20201）获国家药品监督管理局药品审评中心（CDE）批准开展临床，治疗急性缺血性脑卒中。这是CDE批准的国内首款间充质基质细胞药的临床试验申请 ...

This vascular deficiency correlated with the presence of a dense stromal matrix that is a prominent histological hallmark of PDA tumours. Therapeutic targeting of stromal cells decreased the stroma ...